Clinical trial · Observational
Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma
Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma - a Mixed Method Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pirmary endpoint: to examine the feasibility of using an mHealth app for reporting of side effects instead of a telephone call from the hospital staff together with examining the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. Usual procedure to assess side effect prior to cancer treatment with Bortezomib is a telephone call the day before. With this innovative method investigator aimed to give the patient more independence in their daily life and in that way improve their quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| mHealth app | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Registration of side effects
- description
- patients are to registrer side effects prior to treatment with Bortezomib through an app.
- interventionNames
- Device: mHealth app
Primary outcomes (2)
- measure
- Time registrations of side effects using an app
- timeFrame
- 18 months
- description
- PRO data (time registrations of side effects using an app)
- measure
- patient registration of side effects using an app
- timeFrame
- 18 months
- description
- PRO data
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * patients with MM scheduled for Bortezomib * patients should have access to a smartphone * patients should be able to self-report side effects of Bortezomib using a smartphone app, and be willing to participate in a semi-structured interview. Exclusion Criteria: * patients had to talk and read danish
References
Publications (0)
Data not yet available